GlassScriptPhysician profile
Stuart L Goldberg
NPI 1215996376
$4,646.33
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $545 · 2020: $4,101.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $3,947.21 | 2019-2020 | |
| Agios Pharmaceuticals, INC. | $140.00 | 2019 | |
| Astellas Pharma US INC | $128.49 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $102.73 | 2019-2020 | |
| Incyte Corporation | $99.83 | 2019-2020 | |
| Pfizer INC. | $50.82 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $44.17 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $31.67 | 2019 | |
| Daiichi Sankyo INC. | $28.16 | 2019-2020 | |
| Genzyme Corporation | $14.99 | 2019 | |
| Amgen INC. | $14.98 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $14.98 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.35 | 2019 | |
| Janssen Biotech, INC. | $13.95 | 2020 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Goldberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.